These include elevated levels of autoantibodies in circulation against four melanoma differentiation antigens (gp100, MelanA/MART1, TRP1/TYRP1 and TRP2/TYPR2) and the CT antigen NY‐ESO‐1 (Fassler et al., 2019; Haag et al., 2018), which have been proposed as a method to track ICB response. This evidence concerns the gene TYRP1 and melanoma.